文献速递头颈外科

持续局部麻醉伤口输注用于头颈癌术后疼痛治疗:一项非随机临床试验

Postoperative Pain Treatment With Continuous Local Anesthetic Wound Infusion in Patients With Head and Neck Cancer: A Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2021-01-01

该前瞻性纵向非随机临床研究纳入两组各30例接受头颈消融手术及选择性颈清扫的患者,比较持续局部麻醉伤口输注与标准化阶梯口服镇痛方案。结果显示干预组术后第1至4天平均和最剧烈疼痛强度更低,神经痛更少,活力和疼痛相关生活质量更高,非阿片类镇痛药需求及疼痛治疗升级需求更少,且未观察到导管相关并发症。

要点

  • 持续局部麻醉伤口输注可降低头颈癌术后第1至4天平均和最剧烈疼痛强度。
  • 干预组神经痛更少,活力和疼痛相关生活质量评分更高。
  • 干预组非阿片类镇痛药需求更少,疼痛治疗升级需求更低,未观察到导管相关并发症。

核心结论

  • 持续局部麻醉伤口输注与头颈癌术后疼痛减轻和镇痛药需求减少相关。
  • 该方法扩展了头颈癌术后疼痛的治疗选择。

研究设计与样本

  • 前瞻性纵向非随机临床研究,在单个三级转诊中心开展,时间为2015年12月1日至2017年7月1日。
  • 共纳入两组各30例连续入组的接受头颈消融手术包括选择性颈清扫的患者,从术前观察到术后第4天。
  • 对照组按标准化阶梯口服治疗方案(布洛芬、安乃近、阿片类药物)治疗。
  • 干预组术中放置疼痛导管(InfiltraLong plus FuserPump,Pajunk,罗哌卡因0.2%,3 mL/h),术后72小时拔除。

主要发现

  • 术后第1至4天,干预组平均疼痛强度为1.6(1.4),对照组为2.7(1.8),η2p=0.09(0.01-0.21)。
  • 干预组最大疼痛强度为2.4(2.2),对照组为4.2(2.0),η2p=0.11(0.01-0.24)。
  • 干预组神经痛评分为5.4(3.4),对照组为7.6(5.1),η2p=0.09(0.004-0.22)。
  • 干预组活力评分为56.2(21.5),对照组为43.8(20.9),r=0.29,95%CI 0.01-0.52;疼痛评分为66.8(27.3),对照组为49.5(27.7),r=0.31,95%CI 0.04-0.54。
  • 干预组请求非阿片类镇痛药者17例(57%),对照组29例(97%),ϕ=0.47,95%CI 0.30-0.67;需要升级疼痛治疗者3例(10%),对照组9例(30%),布洛芬平均剂量500(173)mg vs 1133(650)mg,r=0.64,95%CI 0.02-0.91。

临床怎么用

  • 对于接受消融手术及选择性颈清扫的头颈癌患者,可考虑术中放置持续局部麻醉伤口输注导管以改善术后镇痛。
  • 该方案可能减少非阿片类镇痛药需求和疼痛治疗升级需求,并改善活力和疼痛相关生活质量。
  • 研究中未观察到导管相关并发症,但需结合患者具体情况评估适用性。

局限性

  • 本研究为非随机设计,可能存在选择偏倚。
  • 研究在单个三级转诊中心开展,样本量较小(每组30例),外推性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Up to 80% of patients with head and neck cancer undergoing ablative surgery and neck dissection develop postoperative pain with detrimental effects on quality of life that also contributes to neuropathic and chronic postoperative pain. OBJECTIVE: To investigate the association of continuous local anesthetic wound infusion with pain management after head and neck surgery. DESIGN, SETTING, AND PARTICIPANTS: This prospective, longitudinal, nonrandomized clinical study carried out in a single tertiary referral center (December 1, 2015, to July 1, 2017) included 2 groups of 30 patients. Patients were consecutively enrolled and presented for ablative head and neck surgery including selective neck dissection and studied from the preoperative through the fourth postoperative day. INTERVENTIONS: The control group was treated according to a standardized escalating oral treatment protocol (ibuprofen, metamizole, opioids). The intervention group was treated with an intraoperatively applied pain catheter (InfiltraLong plus FuserPump, Pajunk, ropivacaine, 0.2%, 3 mL/h) that was removed 72 hours after operating. MAIN OUTCOMES AND MEASURES: Average and maximum pain intensities on a numeric rating scale; quality of life using the acute version of the validated 36-Item Short Form Survey; and neuropathic pain using the validated 12-Item painDETECT questionnaire. Consumption of opioid and nonopioid analgesics and evaluation of catheter-associated complications. RESULTS: During postoperative days 1 through 4, patients of the intervention group (mean [SD] age, 63.2 [13.3 years; 9 [30%] women) experienced lower mean (SD) (1.6 [1.4] vs 2.7 [1.8]; η2p = 0.09 [0.01-0.21]) and maximum (2.4 [2.2] vs 4.2 [2.0]; η2p = 0.11 [0.01-0.24]) pain intensities compared with the control group (mean [SD] age, 62.5 [13.6] years; 5 [17%] women). The intervention group also reported less neuropathic pain (mean [SD], 5.4 [3.4] vs 7.6 [5.1]; η2p = 0.09 [0.004 - 0.22]) and higher quality of life regarding vitality (56.2 [21.5] vs 43.8 [20.9], r = 0.29; 95% CI, 0.01-0.52) and pain (66.8 [27.3] vs 49.5 [27.7], r = 0.31; 95% CI, 0.04-0.54). Patients from the intervention group requested nonopioid analgesics considerably less often (n = 17 [57% ]vs n = 29 [97%]; ϕ = 0.47; 95% CI, 0.30-0.67) associated with a noticeably lower need to escalate pain treatment (n = 3 [10%] vs n = 9 [30%]; mean [SD] ibuprofen dose: 500 [173] mg vs 1133 [650] mg; r = 0.64; 95% CI, 0.02-0.91). No catheter-associated complications were observed. CONCLUSIONS AND RELEVANCE: Continuous anesthetic wound infusion is associated with reduced postoperative pain and decreased demand for analgesics. It therefore expands the treatment options for postoperative pain in head and neck cancer. TRIAL REGISTRATION: German Clinical Trials Register: DRKS00009378.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Gostian M, Loeser J, Albert C, et al. Postoperative Pain Treatment With Continuous Local Anesthetic Wound Infusion in Patients With Head and Neck Cancer: A Nonrandomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2021. PMID: 33830180. doi:10.1001/jamaoto.2021.0327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。